Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZL-1211 |
| Synonyms | |
| Therapy Description |
ZL-1211 is a monoclonal antibody that targets CLDN18.2, potentially leading to antibody-dependent cellular cytotoxicity, activation of antitumor immune response, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 621). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZL-1211 | ZL 1211|ZL1211 | CLDN18.2 Antibody 23 | ZL-1211 is a monoclonal antibody that targets CLDN18.2, potentially leading to antibody-dependent cellular cytotoxicity, activation of antitumor immune response, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 621). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05065710 | Phase Ib/II | ZL-1211 | A Study of ZL-1211 in Patients With Advanced Solid Tumor | Completed | USA | 1 |